Healthcare Industry News: CT
News Release - March 18, 2021
Smith & Nephew's ALLEVYN(TM) LIFE Foam Dressings halved change frequency, significantly reduced cost and improved treatment satisfaction in real-world studyLONDON, March 18, 2021 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped to significantly reduce dressing change frequency and weekly dressing costs, while improving treatment satisfaCTion for clinicians and patients in a community setting.*1
At week 4, compared with previous dressings, ALLEVYN LIFE Dressings significantly reduced mean weekly dressing change frequency by 47.1%*1 and mean weekly dressing costs by 58.7%.*1
A majority of healthcare professionals agreed that ALLEVYN LIFE Dressings performed better than previous dressings for the seven assessed charaCTeristics. Patient satisfaCTion also improved for overall wound care experience, exudate control, and comfort, all despite fewer nursing visits.1
"Frequency of dressing changes is a key cost driver for nurse time, materials and dressings in wound management, and is becoming even more important with the changes to care delivery we have seen driven by the pandemic," said Cathy Dalene, Senior Vice President Global Marketing AWM, Smith & Nephew. "As this recent study has shown, ALLEVYN LIFE Dressings with their change indicator, extended wear time, and excellent exudate management can reduce costs and also help encourage patients to become more involved in their care."
The ambispeCTive observational study was conduCTed at 24 primary care centres and six nursing homes in Spain. ALLEVYN LIFE Dressings were used as either the primary or secondary dressing for 4 weeks instead of the previous dressings, of which 42% were foam dressings and 21% gelling fibres. 94 patients with 128 wounds were included and most were aged over 70 years. The most common wounds were leg ulcers or pressure ulcers, and 25% of all wounds were >12 months in duration.
ALLEVYN LIFE Dressings with EXULOCK™ Advanced Lock-in technology provide effeCTive exudate management,2-5 and high levels of patient comfort and confidence.**4,5 The EXUMASK™ Change Indicator helps patients and carers take ownership of wounds,4 whilst simultaneously providing high patient satisfaCTion as well as saving time through fewer dressing changes.5,6
To learn more about ALLEVYN LIFE dressings please visit www.smith-nephew.com/onemoreday
** Based on a produCT evaluation
- Tiscar-González V, Rodriguez MJM, Rabadán Sainz C, et al. Clinical and economic impaCT of wound care using a polyurethane foam multi-layer dressing versus standard dressings on delayed healing ulcers. Adv Skin Wound Care. 2021;34(1):23-30.
- Smith & Nephew 2012. Simulated Wound Model Testing of ALLEVYN Life and Mepilex Border. Internal Report. DS/12/130/DOF.
- Stephen-Haynes J, Bielby A, Searle R. The clinical performance of a silicone foam in an NHS community trust. Journal of Community Nursing. 2013;27(5):50-59.
- Simon D, Bielby A. A struCTured collaborative approach to appraise the clinical performance of a new produCT. Wounds UK. 2014;10(3):80-87.
- Rossington A, Drysdale, K, and Winter R. Clinical performance and positive impaCT on patient wellbeing of ALLEVYN Life. Wounds UK. 2013;9(4):91-95.
- Joy H, Bielby A, Searle R. A collaborative projeCT to enhance efficiency through dressing change praCTice. J Wound Care. 2015 Jul;24(7):312, 314-7.
Smith & Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our produCT portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith & Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms 'Group' and 'Smith & Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith & Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
To learn more about how we can help you get CLOSER TO ZERO™ human and economic consequence of wounds, please visit www.closertozero.com
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expeCTed revenue growth and trading margins, market trends and our produCT pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expeCT", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important faCTors that could cause aCTual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these faCTors include: risks related to the impaCT of COVID-19, such as the depth and longevity of its impaCT, government aCTions and other restriCTive measures taken in response, material delays and cancellations of eleCTive procedures, reduced procedure capacity at medical facilities, restriCTed access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affeCTing health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government aCTions; produCT defeCTs or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement aCTions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic aCTions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transaCTions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affeCT us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange ACT of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these faCTors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to refleCT any change in circumstances or in Smith & Nephew's expeCTations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew to expand Real Intelligence digital ecosystem and CORI(TM) Surgical System with total hip arthroplasty
Smith & Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS
New data underscores material benefits of Smith & Nephew's OXINIUM(TM) DH Technology and OR3O(TM) Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners